Pharmalittle: Colorado is first U.S. state to cap insulin prices; JP Morgan cuts ties with Purdue

first_img Pharmalittle: Colorado is first U.S. state to cap insulin prices; JP Morgan cuts ties with Purdue About the Author Reprints By Ed Silverman May 24, 2019 Reprints Alex Hogan/STAT Tags drug pricinginsulinlegislationLitigationopioidspharmaceuticalsSTAT+ What’s included? What is it? Log In | Learn More Unlock this article by subscribing to STAT+ and enjoy your first 30 days free! GET STARTED GET STARTEDcenter_img [email protected] Pharmalot Columnist, Senior Writer Ed covers the pharmaceutical industry. STAT+ is STAT’s premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond. And so, another working week is about to end. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about weekend plans. Our agenda is rather modest. We plan to spend time with a short person or two, promenade our official mascot, catch up on our reading, putter around the Pharmalot grounds, and binge watch something or other with Mrs. Pharmalot. And what about you? This is a splendid time of year to enjoy the great outdoors. You could make time to see someone special, especially since this will be an extended break on this side of the pond. Or you could simply plan the rest of your life. Well, whatever you do, have a grand time. But be safe. Enjoy, and see you on Tuesday…Colorado is the first state in the U.S. to cap the price of insulin, thanks to a bill signed into law by Gov. Jared Polis, The Denver Post reports. Diabetics who use insulin to control their blood sugar levels will not pay more than $100 per month for the drug starting in January. The law does not limit what insulin manufacturers can charge insurance companies, and it is expected those insurers will pay the difference. The new law also requires Attorney General Phil Weiser to investigate why drug manufacturers started rapidly raising the price of insulin in recent years. Daily reporting and analysis The most comprehensive industry coverage from a powerhouse team of reporters Subscriber-only newsletters Daily newsletters to brief you on the most important industry news of the day STAT+ Conversations Weekly opportunities to engage with our reporters and leading industry experts in live video conversations Exclusive industry events Premium access to subscriber-only networking events around the country The best reporters in the industry The most trusted and well-connected newsroom in the health care industry And much more Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr. Pharmalot @Pharmalot Ed Silvermanlast_img read more